Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 89

1.

Current approaches to the identification and management of breakthrough disease in patients with multiple sclerosis.

Rudick RA, Polman CH.

Lancet Neurol. 2009 Jun;8(6):545-59. doi: 10.1016/S1474-4422(09)70082-1. Review.

PMID:
19446274
2.

Established disease-modifying treatments in relapsing-remitting multiple sclerosis.

Oh J, O'Connor PW.

Curr Opin Neurol. 2015 Jun;28(3):220-9. doi: 10.1097/WCO.0000000000000202. Review.

PMID:
25923124
3.

Breakthrough disease during interferon-[beta] therapy in MS: No signs of impaired biologic response.

Hesse D, Krakauer M, Lund H, Søndergaard HB, Langkilde A, Ryder LP, Sorensen PS, Sellebjerg F.

Neurology. 2010 May 4;74(18):1455-62. doi: 10.1212/WNL.0b013e3181dc1a94.

PMID:
20439848
4.

Current and future treatments for relapsing-remitting multiple sclerosis.

Birnbaum G.

Curr Opin Drug Discov Devel. 2010 Mar;13(2):214-25. Review.

PMID:
20205055
5.

Treatment effects of immunomodulatory therapies at different stages of multiple sclerosis in short-term trials.

Bates D.

Neurology. 2011 Jan 4;76(1 Suppl 1):S14-25. doi: 10.1212/WNL.0b013e3182050388. Review.

PMID:
21205678
6.

Emerging oral drugs for relapsing-remitting multiple sclerosis.

Gasperini C, Ruggieri S.

Expert Opin Emerg Drugs. 2011 Dec;16(4):697-712. doi: 10.1517/14728214.2011.642861. Epub 2011 Dec 7. Review.

PMID:
22148963
7.

B1 cells are unaffected by immune modulatory treatment in remitting-relapsing multiple sclerosis patients.

Rovituso D, Heller S, Schroeter M, Kleinschnitz C, Kuerten S.

J Neuroimmunol. 2014 Jul 15;272(1-2):86-90. doi: 10.1016/j.jneuroim.2014.04.008. Epub 2014 Apr 24.

PMID:
24814390
8.

Rituximab in relapsing and progressive forms of multiple sclerosis: a systematic review.

Castillo-Trivino T, Braithwaite D, Bacchetti P, Waubant E.

PLoS One. 2013 Jul 2;8(7):e66308. doi: 10.1371/journal.pone.0066308. Print 2013. Review.

9.

Current evidence and therapeutic strategies for multiple sclerosis.

Wingerchuk DM.

Semin Neurol. 2008 Feb;28(1):56-68. doi: 10.1055/s-2007-1019128. Review. Erratum in: Semin Neurol. 2008 Jul;28(3):389.

PMID:
18256987
10.

Definitions of breakthrough disease and second-line agents.

Marriott JJ, O'Connor PW.

Neurol Clin. 2011 May;29(2):411-22. doi: 10.1016/j.ncl.2010.12.005. Review.

PMID:
21439450
11.

Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis.

Simpson D, Noble S, Perry C.

CNS Drugs. 2002;16(12):825-50. Review.

PMID:
12421116
12.

Cognitive impairment and its relation with disease measures in mildly disabled patients with relapsing-remitting multiple sclerosis: baseline results from the Cognitive Impairment in Multiple Sclerosis (COGIMUS) study.

Patti F, Amato MP, Trojano M, Bastianello S, Tola MR, Goretti B, Caniatti L, Di Monte E, Ferrazza P, Brescia Morra V, Lo Fermo S, Picconi O, Luccichenti G; COGIMUS Study Group.

Mult Scler. 2009 Jul;15(7):779-88. doi: 10.1177/1352458509105544.

PMID:
19542262
13.

[Treatment of relapses of multiple sclerosis (a review)].

Brkovich RR, Totolian NA, Sokolov AIu, Ignatov IuD, Skoromets AA.

Zh Nevrol Psikhiatr Im S S Korsakova. 2013;113(10 Pt 2):69-77. Review. Russian.

PMID:
24416811
14.

Emerging oral therapies for multiple sclerosis.

Cohen BA, Rieckmann P.

Int J Clin Pract. 2007 Nov;61(11):1922-30. Epub 2007 Sep 3. Review.

15.

How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?

Brown MG, Kirby S, Skedgel C, Fisk JD, Murray TJ, Bhan V, Sketris IS.

Neurology. 2007 Oct 9;69(15):1498-507. Epub 2007 Aug 15.

PMID:
17699802
16.

Glatiramer acetate-specific antibody titres in patients with relapsing / remitting multiple sclerosis and in experimental autoimmune encephalomyelitis.

Bomprezzi R, Schafer R, Reese V, Misra A, Vollmer TL, Kala M.

Scand J Immunol. 2011 Sep;74(3):219-26. doi: 10.1111/j.1365-3083.2011.02581.x.

17.

Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.

Wingerchuk DM, Carter JL.

Mayo Clin Proc. 2014 Feb;89(2):225-40. doi: 10.1016/j.mayocp.2013.11.002. Review.

PMID:
24485135
18.

[Update on current care guidelines: multiple sclerosis].

[No authors listed]

Duodecim. 2013;129(5):548-9. Review. Finnish.

PMID:
23520898
19.

Predicting responders to therapies for multiple sclerosis.

Río J, Comabella M, Montalban X.

Nat Rev Neurol. 2009 Oct;5(10):553-60. doi: 10.1038/nrneurol.2009.139. Review.

PMID:
19794514
20.

A recommended treatment algorithm in relapsing multiple sclerosis: report of an international consensus meeting.

Karussis D, Biermann LD, Bohlega S, Boiko A, Chofflon M, Fazekas F, Freedman M, Gebeily S, Gouider R, Havrdova E, Jakab G, Karabudak R, Miller A; International Working Group for Treatment Optimization in MS.

Eur J Neurol. 2006 Jan;13(1):61-71. Review.

PMID:
16420394
Items per page

Supplemental Content

Write to the Help Desk